Thomas de Vlaam

Chief Executive Officer

Thomas de Vlaam is the founder and CEO of Amylon Therapeutics, He holds a bachelor's degree in International Medicine and Global Health from the University of Groningen which he studied with the ambition of becoming a neurosurgeon. Unfortunately after a diagnosis of Scheuermann’s disease, Thomas underwent significant spinal fusion surgery in 2011, forcing him to give up on his medical career. Despite the physical challenges and long recovery periods, his dream of helping patients a grew stronger and became an unstoppable driver. He joined ProQR – a biotech company in the Netherlands working on novel drugs to treat rare orphan disorders. As their head of CNS he invented and developed a complete new approach to treat Amyloid disorders and decided to start a new company: Amylon. With some initial capital, that idea turned into Amylon's lead program, a breakthrough therapy for one of today’s most important unmet medical needs.

Daniel (Dan) Curtis Ph.D

Chief Development Officer

Daniel Curtis Ph.D is our Chief Development Officer. Dan joined us in June 2018 having previously held leadership roles with Novartis Institutes for Biomedical Research (NIBR). Dr.Curtis received his B.A. in Molecular, Cellular and Developmental Biology from the University of Colorado, his Ph. D, Biological Chemistry and Molecular Pharmacology from Harvard University, and worked as a Postdoctoral Fellow at the Whitehead Institute for Biomedical Research. He has authored more than 30 articles in the field of neurology, biological chemistry and molecular pharmacology.

Rene Beukema

Chief Corporate Development Officer

René Beukema is Amylon’s Chief Corporate Development Officer and General Counsel. René is a seasoned corporate lawyer in the Dutch biotechnology arena. Prior to joining, René served as Chief Corporate Development Officer and General Counsel at ProQR Therapeutics and Crucell N.V. René is co-founder and advisor of myTomorrows N.V., a Dutch life sciences company. He holds a post-doctoral degree in corporate law from the University of Nijmegen, in co-operation with the Dutch Association of In-house Counsel (Nederlands Genootschap van Bedrijfsjuristen), and a master’s degree in Dutch law from the University of Amsterdam.

Our People

Tsinatkeab (Tsinat) Hailu

Director, Nonclinical Research

Tsinatkeab (Tsinat) Hailu is a scientist with a background in protein folding and directed protein evolution. Tsinat holds a master’s degree in Molecular Cell Biology and Biological Chemistry from VU University Amsterdam. He was a Howard Hughes Medical Institute research scholar at the University of Michigan, Ann Arbor from 2009 to 2014 where he worked on developing in vivo models for studying protein folding. Tsinat was instrumental to Amylon’s inception at ProQR Therapeutics and is part of its founding scientific team. He is responsible for the non-clinical R&D at Amylon.

Maria Bourmpoula

Junior Researcher

Maria Bourmpoula joined Amylon in March 2018 as junior researcher. She has a background in neuroscience holding a master’s degree in Medical Biology from the Radboud University Nijmegen. She has previous experience in CNS research at the University of Patras and the Donders Institute for Brain, Cognition and Behavior in Nijmegen, as well as working on targeted gene expression at Philips, Eindhoven. She is responsible for the execution of non-clinical experiments with AT-010.

Sevgi Fruytier

Operations Manager & Executive Assistant

Sevgi Fruytier joined Amylon in June 2018 as operations manager and executive assistant. She is currently finishing her second master degree, Global Health at Maastricht University, after studying Biomedical Sciences at Leiden University. She has experience in biomedical and clinical research at multiple organizations and has a strong interest in translating science to society. She is responsible for assisting the directors of Amylon with operational and administrative activities.

Supervisory board

Dinko Valerio

Supervisory board member

Dinko Valerio is a scientist and an experienced biotech entrepreneur with experience in both public and private companies as CEO and board member. Mr. Valerio is founder and former CEO of Crucell N.V., a Dutch biotech company, and founder and former general partner of Aescap Venture, a life sciences venture capital firm. Mr. Valerio is a professor in the field of gene therapy of the hematopoietic system at the University of Leiden. He is an author on more than 100 articles in peer-reviewed journals and an inventor on 11 patent-families

Bo Jesper Hansen

Supervisory board member

Dr. Bo Jesper Hansen has been a key figure in shaping the modern European orphan disease market. He previously served as the president and CEO of Swedish Orphan International AB where he was directly involved in bringing over 60 products to market. He is an Author of more than 40 publications in international peer-review scientific journals and has an M.D. in Urology and a Ph.D. from the University of Copenhagen.

Scientific Advisory Board

Thomas Wisniewski

Scientific Advisory Board Member

Thomas Wisniewski is the director of Alzheimer’s disease Center at NYU School of medicine. Dr. Wisniewski obtained his medical degree at Kings College School of Medicine in the UK. He did his Neurology and Neuropathology Residencies at NYU and Columbia-Presbyterian, respectively. He is a board-certified Neurologist and Neuropathologist, who runs an active research laboratory focusing on neurodegenerative disorders, in particular the mechanisms which drive Amyloid deposition in Alzheimer's and prion related diseases.

Philip Scheltens

Scientific Advisory Board Member

Philip Scheltens is director and founder of the Alzheimer Center VUmc Amsterdam. In 2011 he was also appointed scientific director at ‘Pearlstring Institute’ (Parelsnoer Instituut) and appointed member of ‘Royal Academy of Arts and Sciences’ (Koninklijke Academie van Kunsten en Wetenschappen). Under his supervision more than 50 theses appeared and there are more than 665 publications to his name. He is active in many fields and is the initiator of the ‘Deltaplan Dementia’ (Deltaplan Dementie).